Profile
Floris van Delft is the founder of SynAffix BV, where he holds the title of Chief Scientific Officer since 2010.
He previously worked as an Associate Professor at Radboud University Nijmegen.
Dr. van Delft obtained a graduate and doctorate degree from the University of Leiden.
Floris van Delft active positions
| Companies | Position | Start |
|---|---|---|
SynAffix BV
 SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Founder | 2009-12-31 |
Former positions of Floris van Delft
| Companies | Position | End |
|---|---|---|
| Radboud University Nijmegen | Corporate Officer/Principal | - |
Training of Floris van Delft
| University of Leiden | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Floris van Delft
